SMT201600078B - Antagonista del recettore per cgrp - Google Patents
Antagonista del recettore per cgrpInfo
- Publication number
- SMT201600078B SMT201600078B SM201600078T SM201600078T SMT201600078B SM T201600078 B SMT201600078 B SM T201600078B SM 201600078 T SM201600078 T SM 201600078T SM 201600078 T SM201600078 T SM 201600078T SM T201600078 B SMT201600078 B SM T201600078B
- Authority
- SM
- San Marino
- Prior art keywords
- antagonist
- cgrp receptor
- cgrp
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600078B true SMT201600078B (it) | 2016-04-29 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600078T SMT201600078B (it) | 2010-03-30 | 2016-03-21 | Antagonista del recettore per cgrp |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8481546B2 (it) |
| EP (1) | EP2552906B1 (it) |
| JP (1) | JP5908455B2 (it) |
| KR (3) | KR101747477B1 (it) |
| CN (1) | CN102834388B (it) |
| AR (1) | AR080746A1 (it) |
| AU (1) | AU2011233627B2 (it) |
| BR (1) | BR112012024785B1 (it) |
| CA (1) | CA2794950C (it) |
| CL (1) | CL2012002739A1 (it) |
| CY (1) | CY1117593T1 (it) |
| DK (1) | DK2552906T3 (it) |
| EA (1) | EA022815B1 (it) |
| ES (1) | ES2562610T3 (it) |
| HK (1) | HK1174914A1 (it) |
| HR (1) | HRP20160287T1 (it) |
| HU (1) | HUE028735T2 (it) |
| IL (1) | IL221665A (it) |
| MX (1) | MX2012010725A (it) |
| NZ (1) | NZ603231A (it) |
| PE (1) | PE20130340A1 (it) |
| PL (1) | PL2552906T3 (it) |
| PT (1) | PT2552906E (it) |
| RS (1) | RS54608B1 (it) |
| SG (1) | SG183918A1 (it) |
| SI (1) | SI2552906T1 (it) |
| SM (1) | SMT201600078B (it) |
| TW (1) | TWI483937B (it) |
| WO (1) | WO2011123232A1 (it) |
| ZA (1) | ZA201207292B (it) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| EA202190966A1 (ru) * | 2018-10-13 | 2021-10-15 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Пролекарства антагонистов cgrp |
| AU2020210024A1 (en) * | 2019-01-20 | 2021-07-01 | Biohaven Pharmaceutical Holding Company Ltd. | CGRP antagonists for treating migraine breakthrough |
| EA202192793A1 (ru) * | 2019-04-11 | 2022-01-12 | Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи | Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью |
| US20220401439A1 (en) * | 2019-12-17 | 2022-12-22 | Biohaven Pharmaceutical Holding Company Ltd. | Intranasal pharmaceutical compositions of cgrp inhibitors |
| JP2023551146A (ja) * | 2020-11-19 | 2023-12-07 | ファイザー アイルランド ファーマシューティカルズ | Ｃｇｒｐ阻害剤の送達を向上させるための組成物 |
| EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
| EP4320113A1 (en) | 2021-04-09 | 2024-02-14 | Teva Czech Industries s.r.o. | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| CN117624191A (zh) * | 2022-08-30 | 2024-03-01 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| KR20120004541A (ko) * | 2002-06-05 | 2012-01-12 | 브리스톨-마이어스 스큅 컴퍼니 | 칼시토닌 유전자 관련 펩티드 수용체 길항제 |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| CN101495480B (zh) * | 2006-05-03 | 2013-07-10 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active IP Right Grant
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 RS RS20160164A patent/RS54608B1/en unknown
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active IP Right Grant
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Application Discontinuation
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en active Application Filing
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
-
2013
- 2013-02-19 HK HK13102079.5A patent/HK1174914A1/zh unknown
-
2016
- 2016-03-21 SM SM201600078T patent/SMT201600078B/it unknown
- 2016-03-21 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600078B (it) | Antagonista del recettore per cgrp | |
| FR22C1044I2 (fr) | Antagonistes du recepteur cgrp | |
| LTC2579894I2 (lt) | CGRP antikūnai | |
| HK1252279A1 (zh) | 5- ht3受體拮抗劑 | |
| CO6801723A2 (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaidano | |
| DK2794626T6 (da) | E-selectin-antagonistforbindelser | |
| DK2443104T3 (da) | Disubstituerede phthalazin-hedgehog-sti-antagonister | |
| BR112013009636A2 (pt) | terapias à base de ligante de receptor quimiossensorial | |
| BR112013009635A2 (pt) | terapias à base de ligante de receptor quimiossensorial | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| SMT201500293B (it) | Antagonisti del recettore toll-like 3 | |
| ZA201306744B (en) | Antagonists of the interleukin-1 receptor | |
| EP2846799A4 (en) | CGRP RECEPTOR ANTAGONISTS BASED ON SPIROLACTAM | |
| EP2846801A4 (en) | CGRP RECEPTOR ANTAGONISTS BASED ON PYRIDINE | |
| IL244356B (en) | Formulations for cgrp receptor antagonists | |
| HK1211588A1 (en) | Antagonists of chemokine receptors | |
| BR112015005750A2 (pt) | antagonistas peptídicos do receptor de vasopressina-2 | |
| EP2846800A4 (en) | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | |
| GB201213698D0 (en) | Receptor antagonists II | |
| GB201213699D0 (en) | Receptor antagonists II | |
| BR112013011766A2 (pt) | antagonistas espiro-oxindol mdm2 |